Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citiz...
Mario Hose | March 19, 2020 |

CureVac, BioNTech, Valeo Pharma: Where is there still potential?

The race for vaccines against Covid-19 is fierce. Every day there are new water level reports - from setbacks to breakthroughs, everything is there. The Tübingen-based Company CureVac ( NASDAQ: CVAC ) recently started its phase study IIa in Peru and Panama. Around 700 people...
Nico Popp | October 16, 2020 |

Minimizing Mining Risk: The “Hybrid Opportunity Generator”

What sets certain companies apart from most others in the early-stage exploration space? A lot of the time it’s simply thinking outside of the box. In the case of Vancouver, BC-based junior exploration and development company Avrupa Minerals Ltd. (AVU)...
Dave Jackson | December 4, 2020 |

Gold, the Ultimate Safe Haven Asset. A Looming Nobel Prize?

Yesterday, the Nobel prizes in economics were awarded. Unfortunately, gold has been omitted and got nothing. How unfair! But looking at the Dutch central bank press release, gold would have much higher chances if they were the ones granting the prizes and not the Swedish ...
Arkadiusz Sieron | October 16, 2019 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturna...
Streetwise Reports | January 8, 2020 |

AIM ImmunoTech Shares Soar as Japan's NIID Tests Ampligen® as Potential Coronavirus Treatment

Shares of AIM ImmunoTech traded more than 150% higher after the company reported that Japan's National Institute of Infectious Diseases will test its Ampligen® drug as a potential treatment for the coronavirus. Immuno-pharmaceutical company AIM Imm...
Streetwise Reports | March 10, 2020 |

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its all...
Streetwise Reports | April 27, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Buzz on the Bullboards: New energy, heath, and transport opportunities

Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse. It is where our Bullboards – your Bullboards – are a leading forum to discuss these Canadian-listed small-cap businesses. Stocks on both sides of the border...
Jonathon Brown | October 19, 2023 |
1 2
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested